Marcus Lettau

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4227283/publications.pdf

Version: 2024-02-01

44 papers	1,307 citations	304743 22 h-index	361022 35 g-index
44 all docs	44 docs citations	44 times ranked	1793 citing authors

#	Article	IF	Citations
1	Stimulatory and inhibitory activity of STING ligands on tumor-reactive human gamma/delta T cells. OncoImmunology, 2022, 11, 2030021.	4.6	7
2	Erroneous expression of NKG2D on granulocytes detected by phycoerythrinâ€conjugated clone 149810 antibody. Cytometry Part B - Clinical Cytometry, 2021, , .	1.5	4
3	CD30-Positive Extracellular Vesicles Enable the Targeting of CD30-Negative DLBCL Cells by the CD30 Antibody-Drug Conjugate Brentuximab Vedotin. Frontiers in Cell and Developmental Biology, 2021, 9, 698503.	3.7	4
4	The Serine Protease CD26/DPP4 in Non-Transformed and Malignant T Cells. Cancers, 2021, 13, 5947.	3.7	8
5	Intra- and Extracellular Effector Vesicles From Human T And NK Cells: Same-Same, but Different?. Frontiers in Immunology, 2021, 12, 804895.	4.8	11
6	Degranulation of human cytotoxic lymphocytes is a major source of proteolytically active soluble CD26/DPP4. Cellular and Molecular Life Sciences, 2020, 77, 751-764.	5.4	15
7	Bispecific antibodies in acute lymphoblastic leukemia therapy. Expert Review of Hematology, 2020, 13, 1211-1233.	2.2	4
8	Galectin-3 Released by Pancreatic Ductal Adenocarcinoma Suppresses Î³Î´ T Cell Proliferation but Not Their Cytotoxicity. Frontiers in Immunology, 2020, 11, 1328.	4.8	16
9	Chitosan nanoparticles as antigen vehicles to induce effective tumor specific T cell responses. PLoS ONE, 2020, 15, e0239369.	2.5	14
10	Histone Deacetylase Inhibitor Modulates NKG2D Receptor Expression and Memory Phenotype of Human Gamma/Delta T Cells Upon Interaction With Tumor Cells. Frontiers in Immunology, 2019, 10, 569.	4.8	22
11	Granulysin species segregate to different lysosome-related effector vesicles (LREV) and get mobilized by either classical or non-classical degranulation. Molecular Immunology, 2019, 107, 44-53.	2.2	12
12	TGF-Î² enhances the cytotoxic activity of VÎ2 T cells. OncoImmunology, 2019, 8, e1522471.	4.6	43
13	Mechanistic peculiarities of activation-induced mobilization of cytotoxic effector proteins in human T cells. International Immunology, 2018, 30, 215-228.	4.0	11
14	In-depth immunophenotyping of patients with glioblastoma multiforme: Impact of steroid treatment. OncoImmunology, 2017, 6, e1358839.	4.6	37
15	Immunosurveillance by human Î³Î´ T lymphocytes: the emerging role of butyrophilins. F1000Research, 2017, 6, 782.	1.6	20
16	Butyrophilin 3A/CD277â€“Dependent Activation of Human Î³Î´ T Cells: Accessory Cell Capacity of Distinct Leukocyte Populations. Journal of Immunology, 2016, 197, 3059-3068.	0.8	40
17	NKG2D- and T-cell receptor-dependent lysis of malignant glioma cell lines by human Î³Î´ T cells: Modulation by temozolomide and A disintegrin and metalloproteases 10 and 17 inhibitors. OncoImmunology, 2016, 5, e1093276.	4.6	63
18	SDF1Î±â€induced interaction of the adapter proteins Nck and HS1 facilitates actin polymerization and migration in TÂcells. European Journal of Immunology, 2015, 45, 551-561.	2.9	12

#	Article	IF	Citations
19	Novel synthesis of fluorochrome-coupled zoledronate with preserved functional activity on gamma/delta T cells and tumor cells. MedChemComm, 2015, 6, 919-925.	3.4	3
20	Subcellular localization and activation of ADAM proteases in the context of FasL shedding in T lymphocytes. Molecular Immunology, 2015, 65, 416-428.	2.2	33
21	The adapter proteins ADAP and Nck cooperate in T cell adhesion. Molecular Immunology, 2014, 60, 72-79.	2.2	10
22	Differential proteinâ€“protein interactions of full length human FasL and FasL fragments generated by proteolysis. Experimental Cell Research, 2014, 320, 290-301.	2.6	7
23	Identification of SH3 Domain Proteins Interacting with the Cytoplasmic Tail of the A Disintegrin and Metalloprotease 10 (ADAM10). PLoS ONE, 2014, 9, e102899.	2.5	26
24	Down-regulation of the cancer/testis antigen 45 (CT45) is associated with altered tumor cell morphology, adhesion and migration. Cell Communication and Signaling, 2013, 11, 41.	6.5	21
25	Shedding of endogenous MHC class Iâ€related chain molecules A and B from different human tumor entities: Heterogeneous involvement of the â€œa disintegrin and metalloproteasesâ€•10 and 17. International Journal of Cancer, 2013, 133, 1557-1566.	5.1	170
26	Effector Granules in Human T Lymphocytes: Proteomic Evidence for Two Distinct Species of Cytotoxic Effector Vesicles. Journal of Proteome Research, 2011, 10, 1603-1620.	3.7	33
27	Insights into the molecular regulation of FasL (CD178) biology. European Journal of Cell Biology, 2011, 90, 456-466.	3.6	62
28	Effector granules in human T lymphocytes: the luminal proteome of secretory lysosomes from human T cells. Cell Communication and Signaling, 2011, 9, 4.	6.5	23
29	The adapter protein Nck: Role of individual SH3 and SH2 binding modules for protein interactions in T lymphocytes. Protein Science, 2010, 19, 658-669.	7.6	37
30	FasL cross-linking inhibits activation of human peripheral T cells. International Immunology, 2009, 21, 587-598.	4.0	14
31	Identification of SH3 domain interaction partners of human FasL (CD178) by phage display screening. BMC Immunology, 2009, 10, 53.	2.2	18
32	Nck adapter proteins: functional versatility in T cells. Cell Communication and Signaling, 2009, 7, 1.	6.5	89
33	Identification of interaction partners for individual SH3 domains of Fas ligand associated members of the PCH protein family in T lymphocytes. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2009, 1794, 168-176.	2.3	22
34	Posttranslational regulation of Fas ligand function. Cell Communication and Signaling, 2008, 6, 11.	6.5	36
35	2â€Ð DIGE analyses of enriched secretory lysosomes reveal heterogeneous profiles of functionally relevant proteins in leukemic and activated human NK cells. Proteomics, 2008, 8, 2911-2925.	2.2	30
36	Storage, Expression and Function of Fas Ligand, the Key Death Factor of Immune Cells. Current Medicinal Chemistry, 2008, 15, 1684-1696.	2.4	47

#	Article	IF	Citations
37	Novel monoclonal antibodies for the investigation of PCH family proteins. Signal Transduction, 2007, 7, 320-328.	0.4	3
38	Secretory lysosomes and their cargo in T and NK cells. Immunology Letters, 2007, 108, 10-19.	2.5	72
39	Regulation of FasL expression: A SH3 domain containing protein family involved in the lysosomal association of FasL. Cellular Signalling, 2006, 18, 1327-1337.	3.6	37
40	The adaptor protein Nck interacts with Fas ligand: Guiding the death factor to the cytotoxic immunological synapse. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 5911-5916.	7.1	57
41	FasL associated factors and their potential role in the regulation of FasL expression. Signal Transduction, 2005, 5, 195-201.	0.4	3
42	Binding of the Intracellular Fas Ligand (FasL) Domain to the Adaptor Protein PSTPIP Results in a Cytoplasmic Localization of FasL. Journal of Biological Chemistry, 2005, 280, 40012-40024.	3.4	51
43	Considering Fas ligand as a target for therapy. Expert Opinion on Therapeutic Targets, 2005, 9, 119-134.	3.4	37
44	Activation-dependent FasL expression in T lymphocytes and Natural Killer cells. Signal Transduction, 2004, 4, 206-211.	0.4	23